Vaxine
Adelaide, Australia· Est.
AI‑enhanced vaccine developer using the Advax™ adjuvant platform for infectious disease and immunotherapy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $60M
AI Company Overview
AI‑enhanced vaccine developer using the Advax™ adjuvant platform for infectious disease and immunotherapy.
Infectious DiseaseOncologyAllergyNeurology
Technology Platform
Advax™ delta‑inulin polysaccharide adjuvant platform combined with AI‑driven antigen design and TLR‑agonist innate immune activators.
Opportunities
Leveraging the Advax™ adjuvant platform and AI design to accelerate vaccine pipelines and expand into emerging market approvals.
Risk Factors
Regulatory approval timelines, manufacturing scale‑up, and reliance on grant funding could constrain growth.
Competitive Landscape
Vaxine competes with global adjuvant and vaccine developers (e.g., GSK, Sanofi) but differentiates via its delta‑inulin adjuvant and AI‑driven antigen selection.